Tessera Therapeutics IPO
Tessera Therapeutics is developing Gene Writing technology, a new approach to genetic medicine that can write therapeutic messages into the genome. The company's platform aims to make precise, targeted genetic modifications to treat serious diseases that current gene therapy approaches cannot address.
What We Know
Tessera Therapeutics has raised substantial funding, including a $300 million Series C round in 2022 that valued the company at over $3 billion. The company was founded by Flagship Pioneering and has built a significant intellectual property portfolio around its Gene Writing platform. While the company's high valuation and innovative technology make it a potential IPO candidate, no public market timeline has been announced. Tessera continues to advance its platform and therapeutic programs while remaining privately held.
Frequently Asked Questions
Has Tessera Therapeutics had an IPO?
No, Tessera Therapeutics has not had an IPO and remains a private company. The company has raised significant venture funding but has not announced IPO plans.
When is the Tessera Therapeutics IPO date?
No IPO date has been announced for Tessera Therapeutics. The company continues to operate privately with no confirmed public market timeline. Sign up for alerts to stay informed.
How can I buy Tessera Therapeutics stock?
Tessera Therapeutics stock is not currently available for purchase as the company remains private. Shares may only be accessible through private markets or accredited investor channels. Sign up for alerts to stay informed.
Stay Updated on the Tessera Therapeutics IPO
Get real-time alerts when Tessera Therapeutics files for an IPO, prices shares, or begins trading.
Get IPO Alerts